Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 12Gastrointestinal 6Thoracic 4Genitourinary 3Breast 3Head & Neck 2Dermatologic 2

Conditions

Breast Neoplasms 11Triple Negative Breast Neoplasms 8Neoplasm Metastasis 6Stomach Neoplasms 5Colorectal Neoplasms 5Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Melanoma 3Prostatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytosis 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 42Paclitaxel 25Cyclophosphamide 25Carboplatin 23olaparib 21Nivolumab 16fludarabine 15Docetaxel 13aldesleukin 12Gemcitabine 11Fulvestrant 11veliparib 9Bevacizumab 9sargramostim 8palbociclib 8durvalumab 8Trastuzumab 8Magnetic Resonance Spectroscopy 8liposomal doxorubicin 7atezolizumab 7Surveys and Questionnaires 7Ipilimumab 7Blood Specimen Collection 7niraparib 6avelumab 6Taxes 6Specimen Handling 6Interleukin-2 6Fluorouracil 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Leucovorin × Breast × Clear all
NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡